SCHEMBL24766591

SCHEMBL24766591

Clc1cc(-c2cscn2)nc(N2CCOCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 2/20 0.46
▸ MAPT P10636 4/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ RAB9A P51151 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ AR P10275 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ NPC1 O15118 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PIK3R2 O00459 1/20 0.41
▸ PIK3CA P42336 3/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ SMG1 Q96Q15 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17204101 0.78 MAPT (0.61) CNR2MAPTCYP1A2CYP2D6RAB9A
SCHEMBL24766035 0.77 MAPT (0.43) CNR2MAPTCYP1A2CYP2D6RAB9A
SCHEMBL29434142 0.75 CDK1 (0.52) MAPTCYP1A2CYP2D6PIK3CASMG1
SCHEMBL24766835 0.75 CDK1 (0.52) MAPTCYP1A2CYP2D6PIK3CASMG1
SCHEMBL24766032 0.74 PIK3CA (0.51) MAPTCYP1A2CYP2D6KMT2AMEN1
SCHEMBL29434160 0.74 MAPT (0.65) CNR2MAPTCYP1A2CYP2D6RAB9A
SCHEMBL29434159 0.74 MAPT (0.65) CNR2MAPTCYP1A2CYP2D6RAB9A
SCHEMBL971891 0.74 MAPT (0.65) CNR2MAPTCYP1A2CYP2D6RAB9A
SCHEMBL24766046 0.74 CYP1A2 (0.49) MAPTCYP1A2CYP2D6RAB9AKMT2A
SCHEMBL28344176 0.73 ALDH1A1 (0.46) MAPTCYP1A2CYP2D6SMN1; SMN2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340543-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-10-27 — — US disclosed
US-11407737-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-08-09 — — US disclosed
US-11407737-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-08-09 — — US disclosed
US-20220089569-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-03-24 — — US disclosed
WO-2022060996-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340543-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CNR2 2996/4885MAPT 2859/4885CYP1A2 4302/4885
US-11407737-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF CNR2 2996/4885MAPT 2859/4885CYP1A2 4302/4885
US-20220089569-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CNR2 2996/4885MAPT 2859/4885CYP1A2 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback